Regeneron (REGN) Pharmaceuticals announced new and updated data from its advancing oncology pipeline will be shared in seven abstracts at the European Society for Medical Oncology, ESMO, 2025 Meeting, taking place from October 17-21 in Berlin, Germany. Highlights include new Phase 3 C-POST data on an every 6-week dosing regimen for the PD-1 inhibitor Libtayo as adjuvant treatment for cutaneous squamous cell carcinoma, CSCC, with a high risk of recurrence. The new safety and pharmacokinetic data from C-POST being presented at ESMO showcase a patient-centric approach to dosing. Patients received either adjuvant therapy with Libtayo or placebo intravenously, starting with 350 mg every 3 weeks for 12 weeks. The majority of patients were switched to every 6-week dosing after the initial 12 weeks, and the remaining patients continued with dosing every 3 weeks throughout the trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Faces Declining Eylea Sales and Medicare Risks, Justifying Sell Rating
- Novo Nordisk update raises questions on Regeneron approval, says Canaccord
- Regeneron price target raised to $660 from $650 at Citi
- Regeneron announces updated data for DB-OTO due to OTOF gene
- Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments